FDA Adcomms & Kenvue Tylenol Lobbying – News & Analysis

Okay, ⁣here’s a breakdown of the provided text,⁣ summarizing the⁣ key points:

1. personal Note/Introductory Paragraph:

* the author shares links ‍to three YouTube videos.
* They⁢ encourage readers to enjoy⁤ the remaining summer days or prepare for winter.
* They suggest various leisure activities (outdoor enjoyment, streaming, socializing) and emphasize safety.

2. FDA Policy Change (KFF Health News):

* The U.S. Food and ⁣Drug Management (FDA) is considering ending its long-standing practice of using external expert advisory committees to review individual drug applications.
* ‍ ‍ George Tidmarsh, head of the⁢ FDA’s Center for⁢ Drug ⁤Evaluation and research, believes these meetings are redundant and a notable time/work⁣ burden for both the FDA and drug ⁣companies.
* The FDA ⁤still intends to consult committees on broader regulatory issues, but not on specific ⁣drug approvals.
* Tidmarsh acknowledges a benefit of the current system is public transparency into the FDA’s ⁤decision-making process.
* Critics fear this change will reduce public‍ scrutiny of⁢ drug approvals.

3.novo Nordisk Restructuring (Bloomberg News):

*⁤ Novo Nordisk⁣ (maker of Ozempic) ⁣is ‍implementing changes to boost competitiveness against Eli Lilly in the obesity drug‍ market.
* ⁣ New CEO maziar Mike Doustdar is ⁤requiring office employees⁣ to return to⁤ a five-day-a-week in-office⁢ schedule starting January 1st.
* This is accompanied by a 11% workforce reduction.
* The ‍company is shifting away from its previously flexible work culture (common in Denmark, with ⁤emphasis on work-life balance).
* Doustdar has also made other cost-cutting measures, including rescinding job offers, cutting bonuses, and ⁣implementing a hiring freeze.
* ‍ The goal is to create a “performance culture” to compete more effectively with Eli ⁢lilly.

Let me know⁢ if you’d like me ‍to elaborate on any of these⁣ points or analyze the text further!